Transcranial direct current stimulation for depression in Alzheimer's disease: study protocol for a randomized controlled trial

Zui Narita, Yuma Yokoi, Zui Narita, Yuma Yokoi

Abstract

Background: Patients with Alzheimer's disease frequently elicit neuropsychiatric symptoms as well as cognitive deficits. Above all, depression is one of the most common neuropsychiatric symptoms in Alzheimer's disease but antidepressant drugs have not shown significant beneficial effects on it. Moreover, electroconvulsive therapy has not ensured its safety for potential severe adverse events although it does show beneficial clinical effect. Transcranial direct current stimulation can be the safe alternative of neuromodulation, which applies weak direct electrical current to the brain. Although transcranial direct current stimulation has plausible evidence for its effect on depression in young adult patients, no study has explored it in older subjects with depression in Alzheimer's disease. Therefore, we present a study protocol designed to evaluate the safety and clinical effect of transcranial direct current stimulation on depression in Alzheimer's disease in subjects aged over 65 years.

Method: This is a two-arm, parallel-design, randomized controlled trial, in which patients and assessors will be blinded. Subjects will be randomized to either an active or a sham transcranial direct current stimulation group. Participants in both groups will be evaluated at baseline, immediately, and 2 weeks after the intervention.

Discussion: This study investigates the safety and effect of transcranial direct current stimulation that may bring a significant impact on both depression and cognition in patients with Alzheimer's disease, and may be useful to enhance their quality of life.

Trial registration: ClinicalTrials.gov, NCT02351388 . Registered on 27 January 2015. Last updated on 30 May 2016.

Keywords: Alzheimer’s disease; Brain stimulation; Depression; Transcranial direct current stimulation.

Figures

Fig. 1
Fig. 1
Schedule of enrollment, interventions, and assessments. tDCS transcranial direct current stimulation, CDR Clinical Dementia Rating, MMSE Mini Mental State Examination, GDS Geriatric Depression Scale, CSDD Cornell Scale for Depression in Dementia, NPI Neuropsychiatric Inventory, SAS Starkstein Apathy Scale, QOL-AD Quality of Life-Alzheimer’ disease, ZBI Zarit Burden Interview, ADCS-ADL Alzheimer’s Disease Cooperative Study Activities of Daily Living, CGI Clinical Global Impression
Fig. 2
Fig. 2
Flowchart summarizing the trial

References

    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Arlington: American Psychiatric Association; 2013.
    1. Alzheimer’s Disease International. World Alzheimer Report 2015 The global impact of dementia. An analysis of prevalence, incidence, cost and trends. 2015
    1. Rocca WA, Petersen RC, Knopman DS, Hebert LE, Evans DA, Hall KS, et al. Trends in the incidence and prevalence of Alzheimer’s disease, dementia, and cognitive impairment in the United States. Alzheimers Dement J Alzheimers Assoc. 2011;7(1):80–93. doi: 10.1016/j.jalz.2010.11.002.
    1. Ganguli M, Hendrie HC. Screening for cognitive impairment and depression in ethnically diverse older populations. Alzheimer Dis Assoc Disord. 2005;19(4):275–8. doi: 10.1097/01.wad.0000190807.90254.24.
    1. Llibre Rodriguez JJ, Ferri CP, Acosta D, Guerra M, Huang Y, Jacob KS, et al. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. Lancet Lond Engl. 2008;372(9637):464–74. doi: 10.1016/S0140-6736(08)61002-8.
    1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement J Alzheimers Assoc. 2013;9(1):63–75.e2. doi: 10.1016/j.jalz.2012.11.007.
    1. Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ. Epidemiology of dementias and Alzheimer’s disease. Arch Med Res. 2012;43(8):600–8. doi: 10.1016/j.arcmed.2012.11.003.
    1. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80(19):1778–83. doi: 10.1212/WNL.0b013e31828726f5.
    1. León-Salas B, Olazarán J, Muñiz R, González-Salvador MT, Martínez-Martín P. Caregivers’ estimation of patients’ quality of life (QoL) in Alzheimer’s disease (AD): an approach using the ADRQL. Arch Gerontol Geriatr. 2011;53(1):13–8. doi: 10.1016/j.archger.2010.05.021.
    1. León-Salas B, Olazarán J, Cruz-Orduña I, Agüera-Ortiz L, Dobato JL, Valentí-Soler M, et al. Quality of life (QoL) in community-dwelling and institutionalized Alzheimer’s disease (AD) patients. Arch Gerontol Geriatr. 2013;57(3):257–62. doi: 10.1016/j.archger.2013.04.013.
    1. Acosta-Castillo GI, Luisa Sosa A, Orozco R, Borges G. Neuropsychiatric symptoms in older adults with dementia and their relationship to disease severity. Rev Investig Clin Organo Hosp Enfermedades Nutr. 2012;64(4):354–63.
    1. Aalten P, Verhey FRJ, Boziki M, Bullock R, Byrne EJ, Camus V, et al. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord. 2007;24(6):457–63. doi: 10.1159/000110738.
    1. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59(4):577–85. doi: 10.1111/j.1532-5415.2011.03355.x.
    1. Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet Lond Engl. 2011;378(9789):403–11. doi: 10.1016/S0140-6736(11)60830-1.
    1. Gábor G, László T. The efficacy of ECT treatment in depression: a meta-analysis. Psychiatr Hung Magy Pszichiatriai Tarsasag Tudomanyos Folyoirata. 2005;20(3):195–200.
    1. Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004;20(1):13–20. doi: 10.1097/00124509-200403000-00004.
    1. Oudman E. Is electroconvulsive therapy (ECT) effective and safe for treatment of depression in dementia? A short review. J ECT. 2012;28(1):34–8. doi: 10.1097/YCT.0b013e31823a0f5a.
    1. Hausner L, Damian M, Sartorius A, Frölich L. Efficacy and cognitive side effects of electroconvulsive therapy (ECT) in depressed elderly inpatients with coexisting mild cognitive impairment or dementia. J Clin Psychiatry. 2011;72(1):91–7. doi: 10.4088/JCP.10m05973gry.
    1. Rao V, Lyketsos CG. The benefits and risks of ECT for patients with primary dementia who also suffer from depression. Int J Geriatr Psychiatry. 2000;15(8):729–35. doi: 10.1002/1099-1166(200008)15:8<729::AID-GPS193>;2-A.
    1. Fong TG, Jones RN, Shi P, Marcantonio ER, Yap L, Rudolph JL, et al. Delirium accelerates cognitive decline in Alzheimer disease. Neurology. 2009;72(18):1570–5. doi: 10.1212/WNL.0b013e3181a4129a.
    1. Brunoni AR, Nitsche MA, Bolognini N, Bikson M, Wagner T, Merabet L, et al. Clinical research with transcranial direct current stimulation (tDCS): challenges and future directions. Brain Stimulat. 2012;5(3):175–95. doi: 10.1016/j.brs.2011.03.002.
    1. Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P. Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry J Ment Sci. 2012;200(1):52–9. doi: 10.1192/bjp.bp.111.097634.
    1. Brunoni AR, Valiengo L, Baccaro A, Zanão TA, de Oliveira JF, Goulart A, et al. The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA Psychiat. 2013;70(4):383–91. doi: 10.1001/2013.jamapsychiatry.32.
    1. Brunoni AR, Moffa AH, Fregni F, Palm U, Padberg F, Blumberger DM, et al. Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. Br J Psychiatry J Ment Sci. 2016;208(6):522–31. doi: 10.1192/bjp.bp.115.164715.
    1. Brunoni AR, Teng CT, Correa C, Imamura M, Brasil-Neto JP, Boechat R, et al. Neuromodulation approaches for the treatment of major depression: challenges and recommendations from a working group meeting. Arq Neuropsiquiatr. 2010;68(3):433–51. doi: 10.1590/S0004-282X2010000300021.
    1. Alonzo A, Brassil J, Taylor JL, Martin D, Loo CK. Daily transcranial direct current stimulation (tDCS) leads to greater increases in cortical excitability than second daily transcranial direct current stimulation. Brain Stimulat. 2012;5(3):208–13. doi: 10.1016/j.brs.2011.04.006.
    1. Suemoto CK, Apolinario D, Nakamura-Palacios EM, Lopes L, Leite REP, Sales MC, et al. Effects of a non-focal plasticity protocol on apathy in moderate Alzheimer’s disease: a randomized, double-blind, sham-controlled trial. Brain Stimulat. 2014;7(2):308–13. doi: 10.1016/j.brs.2013.10.003.
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346 doi: 10.1136/bmj.e7586.
    1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–44. doi: 10.1212/WNL.34.7.939.
    1. Teng E, Ringman JM, Ross LK, Mulnard RA, Dick MB, Bartzokis G, et al. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2008;16(6):469–77. doi: 10.1097/JGP.0b013e318165dbae.
    1. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc. 1992;40(9):922–35. doi: 10.1111/j.1532-5415.1992.tb01992.x.
    1. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4. doi: 10.1212/WNL.43.11.2412-a.
    1. Kørner A, Lauritzen L, Abelskov K, Gulmann N, Marie Brodersen A, Wedervang-Jensen T, et al. The Geriatric Depression Scale and the Cornell Scale for Depression in Dementia. A validity study. Nord J Psychiatry. 2006;60(5):360–4. doi: 10.1080/08039480600937066.
    1. Brunoni AR, Schestatsky P, Lotufo PA, Benseñor IM, Fregni F. Comparison of blinding effectiveness between sham tDCS and placebo sertraline in a 6-week major depression randomized clinical trial. Clin Neurophysiol Off J Int Fed Clin Neurophysiol. 2014;125(2):298–305. doi: 10.1016/j.clinph.2013.07.020.
    1. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10–16. doi: 10.1212/WNL.48.5_Suppl_6.10S.
    1. Pedersen KF, Alves G, Larsen JP, Tysnes O-B, Møller SG, Brønnick K. Psychometric properties of the Starkstein Apathy Scale in patients with early untreated Parkinson disease. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2012;20(2):142–8. doi: 10.1097/JGP.0b013e31823038f2.
    1. Wolak-Thierry A, Novella J-L, Barbe C, Morrone I, Mahmoudi R, Jolly D. Comparison of QoL-AD and DQoL in elderly with Alzheimer’s disease. Aging Ment Health. 2015;19(3):274–8. doi: 10.1080/13607863.2014.927822.
    1. Bédard M, Molloy DW, Squire L, Dubois S, Lever JA, O’Donnell M. The Zarit Burden Interview: a new short version and screening version. Gerontologist. 2001;41(5):652–7. doi: 10.1093/geront/41.5.652.
    1. Niina R, Honma A, Sugai Y. Reliability, validity, and utility of Japanese version of the SIB and the modified ADCS-ADL. Rounen Seishin Igaku. 2005-6;16(6);683-91. Japanese.
    1. Busner J, Targum SD. The Clinical Global Impressions Scale. Psychiatry Edgmont. 2007;4(7):28–37.
    1. Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. Int J Neuropsychopharmacol. 2011;14(8):1133–45. doi: 10.1017/S1461145710001690.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅